血栓栓塞性疾病患者血浆中的纤溶酶 - α2 - 纤溶酶抑制剂复合物

Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.

作者信息

Wada K, Takahashi H, Tatewaki W, Takizawa S, Shibata A

机构信息

First Department of Internal Medicine, Niigata University School of Medicine, Japan.

出版信息

Thromb Res. 1989 Dec 15;56(6):661-5. doi: 10.1016/0049-3848(89)90283-1.

DOI:10.1016/0049-3848(89)90283-1

PMID:2534445

Abstract

Plasmin generation in vivo was assessed by measuring plasma levels of plasmin-a2-plasmin inhibitor complex (PAP) with an ELISA in 42 patients with arterial or venous thromboembolic diseases. Plasma concentration of PAP was markedly elevated in patients with venous thromboembolic diseases during acute illness (3.32 +/- 3.71 ug/ml, mean +/- SD) as compared to healthy subjects (0.24 +/- 0.13 ug/ml, n = 14), while it was nearly normal (0.30 +/- 0.13 ug/ml) in patients with venous thromboembolic diseases in chronic stage. Patients with arterial thromboembolism had modestly elevated PAP; 1.05 +/- 0.77 ug/ml during acute episode, and 0.84 +/- 0.40 ug/ml in chronic stage. These results indicate that excessive activation of fibrinolytic system (plasmin generation in vivo) occurs actually in many patients with thrombotic diseases, especially in venous thromboembolic diseases during acute illness.

摘要

通过酶联免疫吸附测定法（ELISA）检测42例动脉或静脉血栓栓塞性疾病患者血浆中纤溶酶-α2-纤溶酶抑制剂复合物（PAP）水平，以评估体内纤溶酶的生成情况。与健康受试者（0.24±0.13μg/ml，n = 14）相比，静脉血栓栓塞性疾病患者在急性发病期间血浆PAP浓度显著升高（3.32±3.71μg/ml，均值±标准差），而处于慢性期的静脉血栓栓塞性疾病患者血浆PAP浓度接近正常（0.30±0.13μg/ml）。动脉血栓栓塞患者的PAP略有升高；急性发作期为1.05±0.77μg/ml，慢性期为0.84±0.40μg/ml。这些结果表明，在许多血栓性疾病患者中，尤其是急性发病期的静脉血栓栓塞性疾病患者，纤溶系统实际上存在过度激活（体内纤溶酶生成）的情况。